Dulaglutide

Tirzepatide is a single peptide that activates two receptors at once: GIP and GLP-1, the two main incretin hormones your gut releases after eating. It is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea, and it has produced the largest weight-loss numbers of any approved drug to date. Like semaglutide, this is a heavily trialed, fully approved medicine, not a gray-market research compound.

Liraglutide is a once-daily injectable GLP-1 receptor agonist, a synthetic peptide that shares about 97% of its sequence with the natural gut hormone GLP-1 but is engineered with a fatty acid chain so it survives in the body far longer. It is FDA-approved as Victoza for type 2 diabetes (2010) and as Saxenda for chronic weight management (2014), and is one of the most studied drugs in its class. As of 2024 a generic version is also FDA-approved.

CagriSema is a once-weekly injectable that pairs two drugs in one shot: semaglutide (a GLP-1 receptor agonist, the molecule behind Ozempic and Wegovy) and cagrilintide (a long-acting amylin analog). It is being developed by Novo Nordisk for obesity and type 2 diabetes, and in 2025 it cleared its phase 3 REDEFINE trials. It is not yet approved by the FDA, though regulatory filings are underway.

Cagrilintide (also called AM833) is a long-acting synthetic analog of amylin, the gut-brain satiety hormone co-secreted with insulin by pancreatic beta cells. It is an investigational once-weekly injectable being developed by Novo Nordisk for obesity, most prominently as the amylin half of CagriSema (cagrilintide plus semaglutide). It is not yet approved as a standalone drug, but it has cleared phase 2 trials and is in late-stage development.

Eloralintide (Eli Lilly code LY3841136) is an investigational, long-acting, selective amylin receptor agonist given as a once-weekly subcutaneous injection for obesity. Amylin is the satiety hormone your pancreas releases alongside insulin, and eloralintide is built to mimic it without the gut side effects that sink most appetite drugs. It is not approved anywhere yet, but it has cleared Phase 1 and a 263-person Phase 2 trial with weight loss up to roughly 20 percent, and Lilly has said it is moving into Phase 3.

Amycretin is Novo Nordisk's single-molecule agonist of both the GLP-1 and amylin receptors, developed as a once-weekly injection and a once-daily pill. Early trials produced some of the biggest weight-loss numbers seen with any obesity drug so far, and the injectable version entered phase 3 (the AMAZE program) in 2026. It is not approved anywhere, and everything known about it comes from company-run trials of up to 36 weeks.